San Francisco, CA, Jan. 28, 2021 (World NEWSWIRE) — through NewMediaWire — Oncology Pharma Inc. (OTC: ONPH) is pleased to announce that it has retained the services of Mr. James Smith, CPA as its new Chief Financial Officer.
Mr. James Smith, CPA is a seasoned govt officer with working experience encompassing multiple public and private organizations across a selection of industries. His prior expertise consists of CEO and/or CFO in two absolutely reporting SEC registrants as effectively as various OTC Pink Sheet companies in both the CFO, outside accountant or CEO capacities. In addition, for the duration of his employment with two national accounting firms and in his personal CPA business observe, Mr. Smith has labored with many Family members Places of work and buyers in aiding them with their functions, capital placement, organizational approach and composition, with an emphasis on tax and estate organizing.
“I extremely much glance forward to aiding the Oncology Pharma workforce as we even more advance the development and commercialization of a number of exceptional biotechnology prospects. There appears to be like to be a large amount of likely for the suite of systems assembled by the crew and it is enjoyable to be a element of the effort to deliver to fruition the software of these systems to serious earth options to clinical challenges,” reported Mr. Smith in reaction to his appointment.
Oncology Pharma is delighted to welcome Mr. Smith aboard as the Firm is functioning toward increasing its portfolio and financing.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Company”) is at the moment participating in exploration and advancement of therapeutics for oncology and prides by itself for having a planet-class Advisory Board that keeps the Organization in the forefront of establishing systems in cancer investigation, biotechnology, and healthcare.
Ahead Seeking STATEMENTS
Specific of the issues reviewed in this announcement include forward-searching statements that require materials pitfalls to and uncertainties in the Company’s small business that may well result in genuine effects to differ materially from those expected by the statements produced herein. This kind of pitfalls and uncertainties involve pitfalls similar to licensing arrangements and joint ventures, which includes the need to have to negotiate the definitive agreements for the relationships possible failure to understand expected added benefits of organization associations and, expenditures of delivering funding to these small business interactions. Other challenges and uncertainties relating to the Enterprise include things like, amid other matters, present-day negative operating cash flows and a have to have for added funding to finance our functioning system the terms of any further more funding, which could be hugely dilutive and may well contain onerous terms surprising prices and running deficits, and reduce than envisioned profits and revenues uncertain willingness and potential of prospects to adopt new systems and other elements that may perhaps have an affect on additional market place acceptance adverse financial ailments adverse benefits of any lawful proceedings the volatility of our functioning outcomes and economical situation lack of ability to attract or keep competent senior management personnel, such as gross sales and marketing and advertising staff our capacity to establish and manage the proprietary character of our technologies by way of the patent method, as perfectly as our capability to maybe license from other folks patents and patent programs important to develop products the Company’s skill to put into practice its lengthy vary business enterprise system for several applications of its technology the Company’s ability to enter into agreements with any vital marketing and advertising and/or distribution associates and with any strategic or joint venture partners the effects of competitiveness the acquiring and servicing of any vital regulatory clearances relevant to applications of the Company’s technologies administration of growth and, other dangers and uncertainties. This is not a solicitation to acquire or market securities and does not purport to be an examination of the Company’s fiscal place.
For further facts, please get hold of the Oncology Pharma at:
1 Sansome Avenue, Suite 3500
San Francisco, CA 94104
Cellular phone: 415-869-1038
Email: [email protected]